The incidence of PCa increased in the last decade of the twentieth century due to the introduction of prostate-specific antigen (PSA) blood tests and a dramatic increase in PSA screening, as more and more patients were diagnosed with low-risk or indolent disease1. This evidence concerns the gene KLK3 and posterior cortical atrophy.